India is seeing an unhealthy rise in cases of the chronic disease affecting kids, but awareness and resources remain low.

Novo Nordisk has launched its weight-loss drug Wegovy in India, while Eli Lilly's Mounjaro has received regulatory approval, ...

Eli Lillys Mounjaro KwikPen gains approval in India, targeting diabetes and obesity with its dual-action formula for weight ...

India approves Eli Lilly’s Mounjaro KwikPen, a once-weekly injection for type 2 diabetes and obesity, offering dual hormone ...

With Novo Nordisk’s Wegovy already in the market, Eli Lilly is stepping up its game with a patient-friendly pen device, ...

Eli Lilly's once-weekly KwikPen format for Mounjaro has been approved in India, offering an easier delivery system for type 2 ...

India’s drug regulator has given the nod to Eli Lilly’s once-a- week Mounjaro (tirzepatide) injection in the KwikPen format, ...

India’s drug regulator has approved Eli Lilly and Company’s diabetes and obesity drug Mounjaro in a KwikPen presentation, the ...

The global Insulin Delivery Device Market, valued at US$32.6 billion in 2024 stood at US$35.3 billion in 2025 and is ...

Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, ...

Novo Nordisk launches weightloss drug Wegovy in India at competitive prices, facing patent battles and high demand.